Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 27 2024
0mins
Source: Newsfilter
Reverse Stock Split Announcement: Cara Therapeutics will implement a 1-for-12 reverse stock split effective December 30, 2024, reducing its authorized shares from 200 million to approximately 16.67 million in an effort to comply with Nasdaq listing requirements.
Company Overview: Cara Therapeutics focuses on developing treatments for pruritus, with an approved IV formulation of difelikefalin for moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
